>
4Sc AG logo

VSC - 4Sc AG Share Price

€1.38 -0.1  -3.5%

Last Trade - 12/05/21

Sector
Healthcare
Size
Small Cap
Market Cap £62.1m
Enterprise Value £32.4m
Revenue £1.93m
Position in Universe 795th / 1053
Bullish
Bearish
Unlock VSC Revenue
Momentum
Relative Strength (%)
1m -18.9%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -37.6%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
2.30 2.06 4.20 4.17 2.20 2.25 1.40 20.7 -0.4%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, 4Sc AGrevenues increased 3% to EUR2.3M. Net loss increased 36% toEUR19M. Revenues reflect an increase in demand for theCompany's products and services due to favorable marketconditions. Higher net loss reflects Other Research andDevelopment Costs increase of 50% to EUR13.8M (expense),Other income - Balancing value decrease of 99% to EUR9K(income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

VSC Revenue Unlock VSC Revenue

Net Income

VSC Net Income Unlock VSC Revenue

Normalised EPS

VSC Normalised EPS Unlock VSC Revenue

PE Ratio Range

VSC PE Ratio Range Unlock VSC Revenue

Dividend Yield Range

VSC Dividend Yield Range Unlock VSC Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
VSC EPS Forecasts Unlock VSC Revenue
Profile Summary

4Sc AG is a Germany-based clinical-stage biopharmaceutical company that develops small-molecule drugs that target key indications in cancer through epigenetic mechanisms. The Company’s product pipeline includes several anti-cancer drugs, which are in various stages of preclinical and clinical development. Its main products are Resminostat, an orally administered histone deacetylase (HDAC) inhibitor for the treatment of a broad spectrum of oncology indications, both in monotherapy in combination with other anti-cancer drugs; 4SC-202, an orally administered small molecule and epigenetic modulator that inhibits the enzymes lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) 1, 2, 3, and 4SC-208, a small molecule that targets two kinases for Hedgehog/GLI signaling.

Directors
Last Annual December 31st, 2020
Last Interim December 31st, 2020
Public Since February 25, 2008
No. of Shareholders: n/a
No. of Employees: 44
Sector Healthcare
Industry Biotechnology & Medical Research
Index Xetra Prime All Share ,
Exchange XETRA
Shares in Issue 50,570,045
Free Float (0.0%)
Eligible for
ISAs
SIPPs
VSC Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for VSC
Upcoming Events for VSC
Tuesday 10th August, 2021
Half Year 2021 4Sc AG Earnings Call
Monday 9th August, 2021 Estimate
Q2 2021 4Sc AG Earnings Release
Monday 18th October, 2021 Estimate
Q3 2021 4Sc AG Earnings Release
Frequently Asked Questions for 4Sc AG
What is the 4Sc AG share price?

As of 12/05/21, shares in 4Sc AG are trading at €1.38, giving the company a market capitalisation of £62.1m. This share price information is delayed by 15 minutes.

How has the 4Sc AG share price performed this year?

Shares in 4Sc AG are currently trading at €1.38 and the price has moved by -17.34% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the 4Sc AG price has moved by -35.75% over the past year.

What are the analyst and broker recommendations for 4Sc AG?

Of the analysts with advisory recommendations for 4Sc AG, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for 4Sc AG is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will 4Sc AG next release its financial results?

4Sc AG is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the 4Sc AG dividend yield?

4Sc AG does not currently pay a dividend.

Does 4Sc AG pay a dividend?

4Sc AG does not currently pay a dividend.

When does 4Sc AG next pay dividends?

4Sc AG does not currently pay a dividend.

How do I buy 4Sc AG shares?

To buy shares in 4Sc AG you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of 4Sc AG?

Shares in 4Sc AG are currently trading at €1.38, giving the company a market capitalisation of £62.1m.

Where are 4Sc AG shares listed? Where are 4Sc AG shares listed?

Here are the trading details for 4Sc AG:

Country of listing: Germany
Exchange: GER
Ticker Symbol: VSC
What kind of share is 4Sc AG?

Based on an overall assessment of its quality, value and momentum, 4Sc AG is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a 4Sc AG share price forecast 2021?

Shares in 4Sc AG are currently priced at €1.38. At that level they are trading at 0.229% discount to the analyst consensus target price of 0.00.

Analysts covering 4Sc AG currently have a consensus Earnings Per Share (EPS) forecast of -0.54 for the next financial year.

How can I tell whether the 4Sc AG share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like 4Sc AG. Over the past six months, the relative strength of its shares against the market has been -25.34%. At the current price of €1.38, shares in 4Sc AG are trading at -20.03% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the 4Sc AG PE Ratio?

We were not able to find PE ratio data for 4Sc AG.

Who are the key directors of 4Sc AG?

4Sc AG's management team is headed by:

Manfred Ruediger - SUB
Clemens Doppler - CSU
Helmut Jeggle - SUB
Irina Antonijevic - SUB
Jason Loveridge - CMG
Susanne Danhauser-Riedl - OTH
Joerg von Petrikowsky - VSU
Helga Ruebsamen-Schaeff - SUB
Frank Hermann - OTH
Who are the major shareholders of 4Sc AG?

Here are the top five shareholders of 4Sc AG based on the size of their shareholding:

Athos GmbH Corporation
Percentage owned: 63.62% (32.2m shares)
FCP Anlage AG Corporation
Percentage owned: 3.67% (1.85m shares)
Wellington Partners Venture Capital GmbH Venture Capital
Percentage owned: 2.75% (1.39m shares)
Apus Capital GmbH Investment Advisor
Percentage owned: 0.28% (142k shares)
Doppler (Clemens M. Ph.D.) Individual Investor
Percentage owned: 0.02% (7.92k shares)
Similar to VSC
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.